Cancer treatment is becoming increasingly personalised. Instead of selecting therapy only by where a tumour started, doctors can now study its genetic characteristics and identify medicines that target specific weaknesses.
Olaparib is one example of this approach. It is a targeted cancer medicine used for selected patients with ovarian, breast, prostate or pancreatic cancer, particularly when testing identifies certain BRCA1, BRCA2 or related DNA-repair gene mutations.
The medicine is not suitable for every patient with these cancers. Its use depends on the cancer type, stage, previous treatment, genetic test results and the person’s overall health.
Olaparib is an oral prescription medicine belonging to a group of targeted treatments called poly (ADP-ribose) polymerase inhibitors, commonly known as PARP inhibitors.
The original brand of olaparib is Lynparza, developed by AstraZeneca and Merck. Generic olaparib tablets are also available in certain countries.
Olaparib is generally supplied as:
It may be used alone or in combination with another cancer medicine, depending on the diagnosis and approved treatment plan.
The National Cancer Institute’s olaparib information page provides an overview of its recognised uses in ovarian, breast, pancreatic and prostate cancers.
PARP enzymes help cells repair certain forms of DNA damage. Olaparib blocks the activity of these enzymes.
Healthy cells often have several pathways available for repairing DNA. However, cancer cells with defective BRCA1 or BRCA2 genes already have difficulty using an important repair pathway called homologous recombination repair.
When olaparib also blocks PARP-mediated repair, the cancer cells may be unable to correct the accumulating DNA damage. This can stop them from multiplying or cause them to die.
This interaction is sometimes described as synthetic lethality. Two DNA-repair problems that may be survivable individually become destructive to the cancer cell when they occur together.
Olaparib can also trap PARP proteins on damaged DNA. These trapped proteins interfere with DNA replication, placing additional stress on the tumour cell.
The role of olaparib is not identical in every cancer. The following table provides a general comparison.
| Cancer type | Patients who may be considered | Typical role of olaparib | Important treatment context |
|---|---|---|---|
| Ovarian cancer | Selected patients with germline or somatic BRCA mutations, or certain HRD-positive tumours | Maintenance treatment after a response to platinum-based chemotherapy | In some settings, it may be combined with bevacizumab |
| Breast cancer | Patients with germline BRCA-mutated, HER2-negative high-risk early or metastatic breast cancer | Adjuvant treatment after chemotherapy or treatment of metastatic disease | Hormone-receptor status and previous systemic treatment must be considered |
| Prostate cancer | Selected patients with metastatic castration-resistant prostate cancer and qualifying BRCA or other HRR mutations | Used alone after certain hormonal treatments or with abiraterone and a corticosteroid in selected BRCA-mutated disease | Companion diagnostic testing is generally required |
| Pancreatic cancer | Patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma | Maintenance therapy after first-line platinum chemotherapy | The cancer must not have progressed during at least 16 weeks of platinum-based treatment |
Approvals and eligibility requirements differ between countries. Treatment should always follow the locally approved prescribing information.
Ovarian cancer has been one of the most established areas of PARP inhibitor treatment.
Olaparib may be prescribed as maintenance therapy after platinum-based chemotherapy has reduced or stabilised the cancer. Maintenance treatment is intended to extend the period during which the disease remains controlled.
It may be considered in situations such as:
Olaparib may be used in selected patients with HER2-negative breast cancer and an inherited harmful BRCA1 or BRCA2 mutation.
High-Risk Early Breast Cancer
For high-risk early breast cancer, olaparib may be prescribed after surgery and chemotherapy given before or after surgery.
In this setting, the objective is adjuvant treatment. It aims to reduce the risk of the cancer returning rather than treating visible metastatic disease.
The usual treatment duration for this indication is one year, unless the cancer returns or unacceptable toxicity develops earlier.
Patients with hormone-receptor-positive disease may continue appropriate endocrine therapy alongside olaparib under medical supervision.
Metastatic Breast Cancer
Olaparib may also be considered for germline BRCA-mutated, HER2-negative metastatic breast cancer after appropriate chemotherapy.
Patients with hormone-receptor-positive cancer would normally have received endocrine therapy or be considered unsuitable for it.
Genetic testing is therefore central to determining whether olaparib belongs in the treatment plan.
Some advanced prostate cancers carry mutations in genes responsible for homologous recombination repair. These genes include BRCA1 and BRCA2, although other qualifying genes may be relevant for certain olaparib indications.
Olaparib may be used alone for selected patients with HRR gene-mutated metastatic castration-resistant prostate cancer whose disease has progressed after treatment with enzalutamide or abiraterone.
It may also be combined with:
The FDA has specifically approved olaparib with abiraterone and prednisone or prednisolone for selected adults with BRCA-mutated metastatic castration-resistant prostate cancer. Further information is available in the FDA approval announcement.
Testing is essential because the evidence and regulatory indications can differ between patients with BRCA mutations and those with alterations in other HRR genes.
Olaparib is not used for every person with pancreatic cancer.
It may be considered as first-line maintenance treatment for adults who have:
In this situation, olaparib may allow the patient to move from intravenous chemotherapy to an oral maintenance treatment.
This does not mean the cancer has been cured. The goal is to delay progression while managing the effects of long-term treatment.
The National Cancer Institute’s explanation of olaparib for pancreatic cancer provides additional information about this treatment approach.
An oncologist may consider olaparib when several clinical and molecular requirements are satisfied.
The FDA maintains a list of authorised companion diagnostic devices used to identify patients for particular targeted medicines.
According to the US prescribing information, the standard tablet dose is generally:
300 mg twice daily, usually taken as two 150 mg tablets in the morning and two 150 mg tablets in the evening.
Olaparib may be taken with or without food. Tablets should be swallowed whole and should not be chewed, crushed, dissolved or divided.
The dose may need to be reduced because of:
If a dose is missed, patients should generally take the next dose at its regular time rather than doubling it. The treating clinician’s instructions should always take priority.
The detailed dosage, adjustment and safety information is available in the FDA prescribing information for Lynparza.
Prices vary significantly by country, pharmacy, manufacturer, pack size, insurance coverage, taxes and patient-assistance programmes.
The following figures are examples of listed Indian retail prices checked on 8 September 2026. They are not quotations or guarantees of availability.
| Product | Type | Manufacturer or marketer | Strength and pack | Listed retail price | Listed MRP |
|---|---|---|---|---|---|
| Lynparza | Branded olaparib | AstraZeneca Pharma India | 150 mg, 56 tablets | Approximately ₹235,489 | ₹287,181.56 |
| Olparib | Generic olaparib | Glenmark Pharmaceuticals | 150 mg, 60 tablets | Approximately ₹9,499 | ₹13,232.34 |
| Olaparib 150 mg | Generic listing | Manufacturer may vary | 150 mg, 60 tablets | Approximately ₹10,513 | ₹12,084 |
A properly authorised generic medicine must contain the same active ingredient and meet the quality, strength and bioequivalence requirements of the regulator that approved it.
However, patients should not assume that every product advertised online has undergone appropriate regulatory review.
Before purchasing generic olaparib, verify:
Regular monitoring helps the oncology team identify side effects before they become severe.
| Monitoring area | Why it matters | Typical approach |
|---|---|---|
| Complete blood count | Detects anaemia, neutropenia and low platelets | Before treatment and generally every month |
| Kidney function | Olaparib exposure can increase when kidney function is reduced | Before and periodically during treatment |
| Liver function | Helps assess the patient’s ability to tolerate treatment | Based on clinical need |
| Respiratory symptoms | Helps identify possible pneumonitis or pulmonary embolism | Report new symptoms immediately |
| Cancer assessment | Shows whether the disease remains controlled | Imaging, examinations and tumour markers as appropriate |
| Medication review | Identifies potentially important drug interactions | At treatment initiation and whenever medicines change |
When blood counts remain low for a prolonged period, treatment may be interrupted and counts checked more frequently. Further haematological investigation may be necessary if recovery does not occur.
Women who could become pregnant are generally advised to use effective contraception during treatment and for six months after the final dose.
Male patients with a partner who is pregnant or could become pregnant should generally use effective contraception during treatment and for three months after the final dose. They should also avoid donating sperm during this period.
Breastfeeding is not recommended during olaparib treatment or for one month after the final dose.
Patients planning a family should discuss fertility preservation and reproductive options with their medical team before starting therapy.
Before purchasing branded or generic olaparib, follow this medicine authenticity checklist to ensure the tablets come from a reliable and properly verified source:
Medical disclaimer: This content is for general education only. It does not replace diagnosis, prescribing advice or treatment from a qualified oncologist. Olaparib is a prescription anticancer medicine and should be used only under specialist supervision.
Abhinav Yadav is a medical content writer with a particular interest in prescription medicines, chronic health conditions and international healthcare access. Her writing explores medicine affordability, global healthcare logistics and the barriers patients may face when seeking treatment across borders.
